ClinicalTrials.gg
CompletedNCT03714373Updated Apr 19, 2024

Open-Label Extension Study of DCCR in PWS Followed by Double-Blind, Placebo-Controlled, Randomized Withdrawal Period

A Phase 3 interventional study of DCCR and DCCR in Prader-Willi Syndrome, sponsored by Soleno Therapeutics, Inc.. Completed at 28 sites in 2 countries. Open to participants aged 4 Years and older. Per ClinicalTrials.gov, last updated 2024-04-19.

Sponsored by Soleno Therapeutics, Inc. (part of Neurocrine Biosciences) · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Aug 2023, 3 years 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
115
Allocation
Randomized
Ages
4 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Prader-Willi Syndrome with a site in United States — 9 open to participants now, 14 under way, 3 of them phase 3. Prader-Willi Syndrome · United States.

Enrollment
10th of 58
115 · median 23
Started
2018
with 9 others
Phase 3
14 of 69
2 open now
Registered
35th of 69
by date
Lead sponsor
5 of 69
Soleno Therapeutics, Inc.

Among the 69 studies in Prader-Willi Syndrome with a site in United States, this one is the 10th largest by enrollment of the 58 interventional ones that give a count, is one of 10 that started in 2018, is one of 14 in phase 3, and was the 35th registered.

Prader-Willi Syndrome

144 studies on the registry are indexed under Prader-Willi Syndrome; 23 are open to participants now.

Browse Prader-Willi Syndrome studies →

Open to participants now

9 of the 69 studies in Prader-Willi Syndrome with a site in United States are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 16 Prader-Willi Syndrome studies recruiting now, 7 (44%) set no upper age limit and 9 (56%) stop at 75 or younger; 11 take children under 18; 1 takes healthy volunteers.

This study: 4 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Prader-Willi Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a multi-center, multi-period study with an open-label period followed by a double-blind, placebo-controlled, randomized withdrawal period evaluating the safety and efficacy of DCCR treatment.

Read the detailed description

115 PWS participants who completed clinical study C601 will be enrolled into the OLE Period. All participants in the Open Label Extension (OLE) Period will receive open-label DCCR. The actual number of participants eligible to enroll in the double-blind, placebo-controlled, randomized withdrawal (RW) period will be limited to those participants taking DCCR in the OLE Period at the time of the RW Period Visit 1 (Baseline/Randomization Visit).The treatment groups in the C602 RW Period are those participants randomized to receive DCCR and those participants randomized to receive Placebo. Participants will be randomized in a 1:1 ratio (DCCR:Placebo).

03

Conditions studied

  • Prader-Willi Syndrome

Browse trials for

Keywords

  • PWS
  • Prader-Willi Syndrome
04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

OLE Period Key Inclusion Criteria:

  • Successful completion of clinical study C601
  • Provide voluntary, written (parent(s) / legal guardian(s) of patient); provide voluntary, written assent (subjects, as appropriate)

OLE Period Key Exclusion Criteria:

  • Positive urine pregnancy test (in females of ) or females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 90 days after study participation
  • Any new disease, condition, or circumstance which would prevent, in the opinion of the Investigator, the patient from completing all study visits and assessments required by the protocol (e.g., an anticipated change of care setting)

RW Period Key Inclusion Criteria:

  • Provide voluntary, written informed consent (parent[s] / legal guardian[s] of participant); provide voluntary, written assent (participants, as appropriate); this includes consent for randomization and potential treatment with placebo for up to 16 weeks
  • Currently participating in clinical study C602 and complete the OLE End of Treatment Visit procedures

RW Period Key Exclusion Criteria:

  • Positive urine pregnancy test (in females of child-bearing potential)
  • Females who are pregnant or breastfeeding, and/or plan to become pregnant or to breast-feed during or within 30 days after study participation
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
115 participants (actual)

Study arms

  • Experimental
    OLE DCCR

    75 - 525 mg DCCR

    Drug: DCCR

  • Experimental
    RW DCCR

    75 - 525 mg DCCR

    Drug: DCCR

  • Placebo comparator
    RW Placebo

    75 - 525 mg Placebo for DCCR

    Drug: Placebo for DCCR

Interventions

06

What researchers measure

Primary outcomes

  1. Assess the safety of DCCR by evaluating the incidence and severity of adverse events reported

    Safety analyses will be conducted in all participants who receive at least one dose of DCCR. Adverse events will be described by type and level of severity.

    Time frame: Baseline to end of OLE (up to 4 years)

  2. Change from RW Period Baseline in HQ-CT Total Score

    Hyperphagia-related behaviors will be assessed by the hyperphagia questionnaire for clinical trials (HQ-CT), an instrument designed to measure symptoms of food related preoccupations and behaviors. The HQ-CT consists of nine items with responses ranging from 0-4 (best to worst). Scores from 9 items will be summed for a possible total score range of 0-36.

    Time frame: RW Period Baseline to Week 16

Secondary outcomes

  1. Change from Baseline in HQ-CT Total Score

    Hyperphagia-related behaviors will be assessed by the hyperphagia questionnaire for clinical trials (HQ-CT), an instrument designed to measure symptoms of food related preoccupations and behaviors. The HQ-CT consists of nine items with responses ranging from 0-4 (best to worst). Scores from 9 items will be summed for a possible total score range of 0-36.

    Time frame: Baseline to end of OLE (up to 4 years)

  2. Change in Body Fat Mass

    Change in Body Fat Mass (kg) using DXA

    Time frame: Baseline to end of OLE (up to 4 years)

  3. Clinical Global Impression of Improvement (CGI-I)

    CGI-I is a single statement designed to assess the Investigator's overall perception of change in the subject's condition across the course of the clinical trial. The Investigator provides a response to "Compared to the subject's condition at enrollment, the subject's condition is:" by rating the subject's behavior using a 7-point response scale (best to worst).

    Time frame: RW Period Week 16

  4. Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a single statement designed to assess the Investigator's overall perception of the severity of the participant's illness across the course of the clinical trial. The Investigator provides a response to "Considering your total clinical experience with this particular population, how ill is this participant at this time:" by rating the subject's behavior using a 7-point response scale (best to worst).

    Time frame: RW Period Week 16

  5. Assess the safety of DCCR by evaluating the incidence and severity of adverse events reported

    Safety analyses will be conducted in all participants who receive at least one dose of randomized withdrawal study drug. Adverse events will be described by type and level of severity.

    Time frame: through the end of the RW Period, 16 weeks

07

Study locations

28 sites
  • University of California, Irvine
    Orange, California 92868, United States
  • Stanford University
    Palo Alto, California 94305, United States
  • Rady Children's Hospital San Diego
    San Diego, California 92123, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • University of Florida Gainesville
    Gainesville, Florida 32608, United States
  • Emory Children's Center
    Atlanta, Georgia 30322, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Kansas University Medical Center
    Kansas City, Kansas 66160, United States
  • National Institutes of Health Hatfield Clinical Research Center
    Bethesda, Maryland 20892, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Sparrow Clinical Research Institute
    Lansing, Michigan 48912, United States
  • Children's Minnesota
    Saint Paul, Minnesota 55102, United States
  • St. Joseph's University Medical Center
    Paterson, New Jersey 07503, United States
  • NYU Winthrop Hospital
    Mineola, New York 11501, United States
  • University Hospitals Cleveland Medical Center
    Cleveland, Ohio 44106, United States
  • The Research Institute at Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Vanderbilt University
    Nashville, Tennessee 37212, United States
  • Research Institute of Dallas
    Dallas, Texas 75231, United States
  • University of Utah
    Salt Lake City, Utah 84108, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • The Queen Elizabeth University
    Glasgow, Scottland G51 4TF, United Kingdom
  • Hull and East Yorkshire Hospitals NHS Trust
    Hull, Yorkshire HU3 2JZ, United Kingdom
  • Birmingham Women's and Children's Hospital
    Birmingham, B4 6NH, United Kingdom
  • Fulbourn Hospital
    Cambridge, CB21 5ER, United Kingdom
  • Aintree University Hospital NHS Foundation Trust
    Liverpool, L9 7AL, United Kingdom
  • Royal London Hospital
    London, E1 1BB, United Kingdom
  • Chelsea and Westminster Hospital
    London, SW10 9NH, United Kingdom
  • Hammersmith Hospital
    London, W12 OHS, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2018 to primary completion in Aug 2023, 58 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2018
First posted
Oct 22, 2018
StartActual
Oct 1, 2018
Primary completionActual
Aug 17, 2023
CompletionActual
Aug 17, 2023
Last update
Apr 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03714373
Responsible party
Sponsor
First posted
Oct 22, 2018
Start date
Oct 1, 2018
Primary completion
Aug 17, 2023
Completion
Aug 17, 2023
Last update
Apr 19, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Diazoxide choline

Start the discussion